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Growth arrest, inhibition of cell proliferation, apoptosis, senescence, and differentiation
are the most characterized effects of a given tumor suppressor response. It is becoming
increasingly clear that tumor suppression results from the integrated and synergistic activ-
ities of different pathways. This implies that tumor suppression includes linear, as well as
lateral, crosstalk signaling. The latter may happen through the concomitant involvement
of common nodal proteins. Here, we discuss the role of Promyelocytic leukemia protein
(PML) in functional cross-talks with the HIPPO and the p53 family tumor suppressor path-
ways. PML, in addition to its own anti-tumor activity, contributes to the assembly of an
integrated and superior network that may be necessary for the maximization of the tumor
suppressor response to diverse oncogenic insults.
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THE HIPPO PATHWAY
First identified in Drosophila, the Hippo (Hpo) signaling path-
way is a conserved string of molecular events, which regulates
the proper size of organs through the balance of cell growth
and cell death. Cell density and contact inhibition information
are conveyed by membrane complexes through the Hpo pathway
to specific transcriptional programs in the nucleus. In contact-
inhibited cells, the Hpo pathway is activated, whereas in sparsely
populated cells, it is inhibited. The pathway is characterized by
a core kinase, Hpo (Mst1 and Mst2 in mammals), and its down-
stream effector, Warts (Wts) kinase (Lats1 and Lats2 in mammals),
which regulate Yorkie (Yki), protein (YAP and TAZ in mammals),
a transcriptional co-activator for transcription factors involved
in the induction of cell proliferation, survival, and apoptosis
(Figures 1A,B).
As the Hpo pathway plays an important role in organ size
control. Loss of function of many individual members of the path-
way leads to tumorigenesis. Accordingly, down-regulation of this
pathway is frequently associated with human cancers. In addi-
tion, the Hpo pathway has been implicated in tissue homeostasis
through the regulation of stem cells, cell differentiation, and tissue
regeneration.
THE DROSOPHILA HIPPO PATHWAY
The“blueprint”for the Hpo pathway emerged from genetic screens
of Drosophila, Wts was the first identified Hpo pathway member
(Justice et al., 1995), encoding a kinase of the Nuclear Dbf-2-
related (NDR) family. Several years later, four tumor suppressors,
named Hpo, Wts, Salvador (Sav), and Mats were implicated in
the regulation of organ size in flies (Figure 1A). These pro-
teins constitute the core kinase cassette of the pathway, whose
products can affect proliferation without increasing susceptibility
to apoptosis (Justice et al., 1995; Tapon et al., 2002; Wu et al.,
2003; Lai et al., 2005). Wts activity, which is fundamental for the
phosphorylation-dependent regulation of Yki (Huang et al., 2005;
Oh and Irvine, 2008), is regulated through a series of phospho-
rylation events. Wts is directly phosphorylated by Hpo and this
phosphorylation is facilitated by Sav protein (Tapon et al., 2002;
Wu et al., 2003). Hpo is a member of the Sterile-20 family of
Ser/Thr kinases. It interacts with and phosphorylates Sav, which
in turn activates Hpo kinase function. Mob as tumor suppressor
(MATS) is similar to Sav and acts as an adaptor protein. Mats also
belongs to the NDR family and binds Wts, potentiating its intrin-
sic activity (Lai et al., 2005). Hpo phosphorylates Mats, increasing
its binding affinity to Wts and potentiating Wts kinase activity
(Praskova et al., 2008).
Located upstream of the Hpo pathway are Merlin (Mer) and
Expanded (Ex; Boedigheimer et al., 1993; LaJeunesse et al., 1998;
Hamaratoglu et al., 2006). These are considered tumor suppressors
that cooperate with each other to control organ growth. Kibra, a
newly discovered member of the Hpo pathway, is involved in for-
mation of a Kibra-Mer-Ex, which constitutes an apical protein
complex required for the association of the Hpo pathway with cel-
lular membranes (Genevet et al., 2010; Yu et al., 2010). Crumbs
(Crb) is a transmembrane protein involved in determining cell
polarity. The loss of Crb expression was shown to further deter-
mine a phenotype characterized by overgrowth (Chen et al., 2010;
Ling et al., 2010; Robinson et al., 2010). It is likely that Crb is
one of the membrane receptors that regulate the Hpo pathway.
Other proteins involved in cell polarity control have been linked
to the Hpo pathway as well, including: Scribble (Scrib), Disk large
(Dlg), Lethal giant larvae (Lgl), and a typical protein C (aPKC;
Chen et al., 2010; Grzeschik et al., 2010). The atypical cadherin
FAT (Ft) was the first transmembrane protein shown to affect
Hpo signaling and was the first tumor suppressor gene isolated
in Drosophila. Complete knock-out of the Ft protein induced
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FIGURE 1 | (A)The Drosophila Hippo pathway. Signaling diagram of Hippo
(Hpo) kinases cascade and of its modulation by apical transmembrane
protein complexes and proteins involved in cell polarity control (Arrowed or
blunted ends indicate activation or inhibition, respectively). (B) Role of YAP
in the Hpo-like pathway in human. In mammals the relationships between
Drosophila Hpo andWts, are conserved in Mst1/2 (Hpo homologs) and
Lats1/2 (Wts homolog). Lats1/2 phosphorylatesYAP on different conserved
motifs. Phosphorylation-dependent 14-3-3 binding and cytoplasmic
retention are conserved inYAP, which inhibits it to enhance the
transcriptional activation of pro-proliferation genes. Depending on the
cellular context Lats1/2 phosphorylatesYAP, increasing its transcriptional
support to p73 to induce apoptosis. YAP can also be phosphorylated by
other kinase, such as CDK1δ/ε promoting its subsequent protein
proteasome-degradation. The retention of YAP at cytoplasmic level can also
be exerted by sequestering the protein at the junctional level through the
interaction with the AMOT protein.
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cell death in Drosophila larvae with overgrown imaginal disks
(Mahoney et al., 1991). Many lines of evidence suggest that the
principal mechanism exerted by Ft is on the Wts function (Feng
and Irvine, 2007, 2009). Many Ft partners were identified as poten-
tial modulators of the Hpo Pathway: (i) Dachsous (Ds), an atypical
cadherin which binds to Ft (Matakatsu and Blair, 2004, 2006); (ii)
Four-jointed (Fj), a kinase that typically localizes to the Golgi sub-
cellular compartment (Ishikawa et al., 2008); (iii) a Casein I kinase,
termed Dco (Disks overgrown), responsible for Ft phosphoryla-
tion in its cytoplasmatic segment (Cho et al., 2006; Feng and Irvine,
2009); and (iv) Dachs, which is an unconventional myosin that
antagonizes Ft (Cho et al., 2006). All of these components are
believed to be responsible for linking Hpo to extracellular stimuli
(Harvey and Tapon, 2007).
Yorkie, a critical effector of the Hpo pathway, is not a direct
transcriptional factor but is a potent transcriptional co-activator
cooperating with different DNA binding proteins. Wts phospho-
rylates Yki at Ser 168, thus creating a binding site for 14-3-3
proteins, which in turn sequester Yki in the cytoplasm and prevent
its nuclear import (Dong et al., 2007b; Oh and Irvine, 2008). Loss
of Hpo signaling, as well as mutations in the 14-3-3 binding site for
Yki, were shown to produce strong nuclear accumulation coupled
with enhanced activity of Yki (Zhao et al., 2007). Interestingly,
some binding partners of Yki are the same kinases that function
upstream to it in the Hpo pathway (e.g., Ex,Wts, and Hpo; Badouel
et al., 2009; Oh et al., 2009). Other partners are represented by tran-
scription factors that govern different classes of genes. One class
includes genes involved in cell survival and proliferation: scalloped
(Sd), a member of TEAD/TEFs family (Wu et al., 2008; Zhang et al.,
2008), and Homothorax (Hth), both of which promote cell pro-
liferation (Peng et al., 2009). Sd, together with Yki, up-regulate
transcription of Diap1 gene, an apoptosis inhibitor (Wu et al.,
2008). Hth is involved in regulating the transcription of another
Yki target, the growth promoting microRNA gene, bantam. Other
Yki targets in this class are the cell-cycle regulators Cyc E, E2F1,
and dMyc (Drosophila Myc; Goulev et al., 2008; Peng et al., 2009;
Neto-Silva et al., 2010). The second class of genes are components
of other signaling pathways including Notch, Wnt, EGFR, and Jak-
Stat pathways. For example, Smad proteins are functional partners
of Yki, potentiating the transcriptional response to BMP/TGF-β
signaling (Alarcon et al., 2009). Finally, a third class of Yki targets
consists of several proteins from its own Hpo cascade, including
Ex, Mer, Kibra, Crb, and Fj (Cho et al., 2006; Hamaratoglu et al.,
2006; Genevet et al., 2009, 2010).
THE MAMMALIAN HIPPO PATHWAY
The Hpo pathway is evolutionarily conserved in mammals
(Figure 1B). It was reported that loss of function in mutant flies
can be rescued by expressing their respective human counterparts
(Wu et al., 2003; Lai et al., 2005). One ortholog for the adaptor
protein Sav, termed WW45 or SAV1, and two orthologs for Mats,
termed MOBKL1A and MOBKL1B have been identified. These
proteins form a conserved kinase cassette that phosphorylates and
inactivates the mammalian Yki homologs, YAP and TAZ, prevent-
ing their nuclear translocation and consequently attenuating the
transcription of genes involved in proliferation and differentiation
(Huang et al., 2005; Zhao et al., 2007; Lei et al., 2008).
MST1/2 are serine-threonine kinases, which are able to ini-
tiate apoptosis when overexpressed (Lin et al., 2002; Ura et al.,
2007). MSTs become activated by auto-phosphorylation on threo-
nine residues within their activation loop domain. The inhibition
of dimerization and auto-phosphorylation of MST2 exerted by
the proto-oncogene serine/threonine protein kinase RAF1 was
reported (O’Neill et al., 2004). In this latter context, expression
of the scaffold protein RASSF1A is able to release MST2 from
this inhibition, thus inducing apoptosis (Matallanas et al., 2007).
Moreover, it was shown that PP2A phosphatase dephosphory-
lates MST1/2 kinases, thus inhibiting their function (Ribeiro et al.,
2010). MST substrates include LATS and MOB1. LATS1/2 kinases
control cellular homeostasis, negatively regulating cell division
cycle 2 (CDC2) and favoring G2/M arrest (Yang et al., 2001; Xia
et al., 2002; Yabuta et al., 2007). LATS2 was also reported to induce
G1/S arrest (Li et al., 2003). The loss of LATS1/2 was shown to
lead to a broad variety of tumors, such as soft tissue sarcoma and
leukemia (St John et al., 1999). These proteins are strong tumor
suppressors. LATS activity is supported by MOB1, which binds to
and activates LATS kinases, favoring YAP and TAZ proto-oncogene
phosphorylation and inhibiting their nuclear activity.
The mammalian genome contains orthologs for most of the
reported upstream regulators of the Hpo pathway in flies. Notably,
it encodes more than one paralog for most of the Drosophila
Hpo components. Two homologs were identified for Kibra:
KIBRA/WWC1 and WWC2,as well as for Ex: FRMD6 and FRMD1,
while only one homologous was identified for Mer: NF2. Par-
alogs for MST and LATS kinases are well characterized and Yki
orthologs, YAP and TAZ exhibit similar function in regulating
signals related to cell growth or apotosis. The presence of con-
served Drosophila orthologs in the mammalian Hpo pathway may
very well serve as a mechanism of redundancy that protects the
organism against cancer-causing mutations.
YAP: A CRITICAL COMPONENT OF THE HIPPO PATHWAY
Yes-associated protein (YAP) was identified as Yes (and Src) kinase-
interacting protein (Sudol, 1994; Sudol et al., 1995). The complex
between YAP and Yes was recently validated functionally in colon
cancer cells by the Bill Hahn laboratory (Rosenbluh et al., 2012).
Originally, YAP was shown as a transcriptional co-activator that
binds the PPxY motif in Runx1 (or AML1 for acute myeloid
leukemia 1; Chen and Sudol, 1995; Yagi et al., 1999). Soon after,
it was reported that YAP, like its paralog TAZ, binds 14-3-3 in a
phospho-dependent manner (Kanai et al., 2000) and YAP plays a
role as a co-activator for the TEAD/TEF family of transcription
factors (Vassilev et al., 2001; Basu et al., 2003). The conserved Hpo
pathway kinase cassette triggers the phosphorylation and inac-
tivation of YAP, preventing its nuclear import and consequently
attenuating the transcription of genes regulating proliferation
(Huang et al., 2005; Zhao et al., 2007; Lei et al., 2008).
At least eight different splicing isoforms of YAP exist (Komuro
et al., 2003; Gaffney et al., 2012). YAP orthologs in lower organ-
isms, such as Drosophila, have tandem WW domains, indicating
that the double WW domain organization is conserved from the fly
to humans. The WW is a small modular protein domain that has
two conserved Tryptophan (W) residues (Bork and Sudol, 1994;
Sudol et al., 1995). The WW domain shares a similar function with
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the SH3 domain, able to bind short peptides that are Proline-rich.
Initially, the WW domain was shown to bind to Proline-rich pep-
tides terminated with Tyrosine (Y), so called PY motifs (Chen and
Sudol, 1995; Einbond and Sudol, 1996; Sudol and Hunter, 2000).
YAP has been found to interact with various proteins of diverse
functions and the majority of these interactions occur through
the YAPs WW domains (reviewed in Bertini et al., 2009; Sudol,
2010, 2012; Sudol and Harvey, 2010). Apart from WW domains,
the modular structure of YAP contains a TEAD factor-binding
domain (TB), which is located at the amino-terminal portion of
the protein (Vassilev et al., 2001), a carboxy-terminal SH3 binding
region, transcriptional activation domain and PDZ-binding motif,
which is critical for nuclear translocation and indispensable for
binding the PDZ motif of ZO-1 and ZO-2 (Oka and Sudol, 2009;
Oka et al., 2010). None of the signaling pathways known is as rich
in WW domain-containing proteins as the Hpo pathway (Sudol
and Harvey, 2010). The intact WW domains of YAP are required
for their co-transcriptional activator function and promoting cell
proliferation (Zhao et al., 2009).
The activation of the Hpo pathway triggers the inhibition of
YAP activity (Figure 1B). YAP is phosphorylated by LATS on dif-
ferent serine residues, among them, serine 127 appears to be the
most critical for its function (Basu et al., 2003). This phosphory-
lation generates a 14-3-3 binding site on YAP, which induces its
cytoplasmic retention, thus inhibiting its co-transcriptional activ-
ity (Basu et al., 2003; Zhao et al., 2007; Hao et al., 2008). YAP is
also phosphorylated by LATS on Ser 381 (Zhao et al., 2010). The
Ser 381 modification primes YAP to subsequent CK1δ/ε phospho-
rylation and degradation via the SCF (beta-TRCP) E3 ubiquitin
ligase complex.
Hippo pathway activation is also triggered by cell–cell contacts.
High-cell density induces YAP phosphorylation and cytoplasmic
retention (Zhao et al., 2007) and the disruption of cell–cell junc-
tions in epithelial tissue, induces nuclear translocation of YAP and
TAZ (Varelas et al., 2010).
There are phosphorylation-independent mechanisms through
which YAP could be sequestered in the cytoplasm. It was observed
that YAP was able to interact with the angiomotin (AMOT) fam-
ily of proteins. This interaction occurs via the WW domains of
YAP and sequesters the protein in the cytoplasm and junctional
complexes (Chan et al., 2011; Wang et al., 2011; Zhao et al., 2011).
The existence of a tripartite complex between AmotL1, YAP, and
ZO-2, which regulates YAP function, apparently in opposite direc-
tions, was highlighted recently (Oka et al., 2012). The cytoplasmic
retention of YAP, exerted by AmotL1, disabled YAP in its nuclear
function,whereas ZO-2 enhanced the nuclear translocation of YAP
(Oka et al., 2012).
Yes-associated protein serves as a co-regulator for various tran-
scriptional factors, including members of the TEAD family fac-
tors, Smad proteins, RUNX, Erb4, and p73 (reviewed in (Sudol,
2010; Mauviel et al., 2012). Among these targets, only the inter-
action with the TEFs/TAEDs appears to be conserved from flies
to humans (Vassilev et al., 2001; Wu et al., 2001; Mahoney et al.,
2005; Sawada et al., 2008). Two major target genes for YAP-TEADs
complexes were described in mammals: CTGF and Cyr61 (Lai
et al., 2011). CTFG is a direct target of YAP-TEADs complex
and was shown to be critical for YAP-induced proliferation and
anchorage-independent growth. Another YAP target is Myc. Sim-
ilar to the Dropsophila Yki-Sd effect on dMyc expression (Neto-
Silva et al., 2010), YAP was shown to up-regulate the expression of
Myc gene in transgenic mouse liver (Dong et al., 2007a). Therefore,
it is not surprising that the targeted disruption of the transcrip-
tional complex of YAP-TEADs by genetic approaches or pharma-
cological compounds is the main focus of drug discovery efforts
aimed at cancers with amplified YAP oncogene (Liu-Chittenden
et al., 2012; Sudol et al., 2012).
As the transcriptional co-activator of SMAD proteins, YAP
seems to also be involved in embryonic stem cell (ESC) pluripo-
tency. The maintenance of this ability by ESC is governed by
coordinating multiple pathways, including TGFβ and BMP path-
ways. Both YAP and TAZ were shown to be critical mediators of
both these pathways. YAP interacts physically with SMADs, driven
by TGFβ and BMP toward their transcriptional function (Vare-
las et al., 2008, 2010; Alarcon et al., 2009; Sudol, 2012). The ESC
pluripotency is described as the ability to give rise to all types of
cells and tissues maintained in adults. Thus, differentiated cells can
also be reprogrammed in ESC-like cells, termed induced pluripo-
tent stem cells (iPSC), by activating a given set of transcription
factors. iPSC cells can then self-renew and differentiate again in
every type of cell and tissue. This ability is due to the activity of dis-
tinct transcription factors such as KLF4, cMYC, OCT4, and SOX2
(Takahashi and Yamanaka, 2006). SMADs proteins were shown to
co-occupy the same genomic site of OCT4 and SOX2 in human
ESC (Mullen et al., 2011). Moreover, YAP was shown to favor, pos-
sibly on a transcriptional level, reprogramming mouse embryonic
fibroblasts in an iPSC-like state (Lian et al., 2010). The majority
of genomic sites for ESCs transcription factors also contain a con-
sensus for TEF/TEADs transcriptional binding factors, suggesting
that YAP could be implicated in this mechanism also through its
interaction with TEADs. Interestingly, it was observed that simul-
taneous knocking down of TEAD1, TEAD3 and TEAD4 inhibits
the ESC pluripotency in mice (Lian et al., 2010).
Many lines of evidence indicate that the Hpo pathway may play
an important role also in mesenchymal stem cells (MSC), which
are able to differentiate into osteoblasts, adipocytes, chondrocytes,
and myoblasts. Consistent with this observation is the discov-
ery of another important YAP transcriptional partner, RUNX2,
which is essential for skeletal mineralization because it stimulates
osteoblast differentiation of MSC, promotes chondrocyte hyper-
trophy, and contributes to endothelial cell migration and vascular
invasion in bone development. Like other RUNT-domain pro-
teins, RUNX2 is a context-dependent transcriptional activator and
repressor of genes that regulate cellular proliferation and differen-
tiation. YAP was shown to interact with full-length RUNX2 in
osseous cells via co-immunoprecipitation of endogenous proteins
and co-immunofluorescence (Zaidi et al., 2004). RUNX2 recruits
YAP to subnuclear foci and to the osteocalcin gene promoter,
but does not affect its nucleo-cytoplasmic shuffling. The signa-
ture Y residue in the PPPYP motif of RUNX2 is essential for
interacting with YAP (Chen and Sudol, 1995; Yagi et al., 1999).
YAP-mediated repression of RUNX2 activity on the osteocalcin
promoter is cell-type independent. YAP-mediated repression of
RUNX2 instead seems to be dependent on the promoter context:
YAP blocked RUNX2-dependent activation of TGFβR1 promoter
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and enhanced RUNX2-dependent repression of its own promoter;
however it did not affect RUNX2 transcriptional effects on the
p6OSE2 or p21 promoters. These data indicate that RUNX2 can
recruit YAP to promoter regions, but the effects of YAP on the
expression of RUNX2 target genes is dependent on the cohort
of other DNA binding proteins and co-factors brought to the
gene by specific DNA sequences and protein–protein interactions.
Transcriptional repression of RUNX2 by YAP depends on Src-
induced activation and tyrosine phosphorylation of YAP (Zaidi
et al., 2004). Dominant-negative Src and YAP proteins, as well as
Src kinase inhibitors, increased RUNX2 transcriptional activation
of the osteocalcin promoter in ROS 17/2.8 cells (Zaidi et al., 2004).
The idea that YAP could support RUNX2 function as co-activator
has been confirmed by a recent study in which authors observed
that a nuclear localized mutant form of YAP can induce osteo-
genesis. It was observed that YAP is part of a signaling complexes
that forms its response to mechanical signals exerted by extracellu-
lar matrix (ECM) rigidity and cell shape. This regulation requires
Rho GTPase activity and tension of the actomyosin cytoskeleton,
but is independent of the canonical Hpo pathway. YAP is required
for differentiation of MSC induced by ECM stiffness and for sur-
vival of endothelial cells regulated by cell geometry (Dupont et al.,
2011).
PML AND p53: A CLOSE LINK IN TUMOR SUPPRESSION
In humans, a complete or partial loss of PML expression has been
observed in multiple types of cancers, including breast, colon,
and prostate (Gurrieri et al., 2004a,b). PML KO mice develop
normally, but are resistant to lethal doses of γ-IR. In addition,
they are prone to tumorigenesis in response to carcinogens, or
an additional oncogenic event, such as the loss of PTEN (Wang
et al., 1998; Trotman et al., 2006). PML is a key factor in the for-
mation of PML nuclear bodies (PML-NBs), which are distinct
nuclear multi-protein complexes that have been associated with
critical cellular processes, including tumor suppression, gene reg-
ulation, post-translational modifications, and protein catabolism.
The stabilization of PML protein levels leads to recruitment of
p53 to the PML-NBs, an event that facilitates p53 acetylation and
transcriptional activation (Pearson et al., 2000; Bernardi and Pan-
dolfi, 2007). It was demonstrated that in conditions of oncogenic
stress, PML is a p53 transcriptional target gene (de Stanchina et al.,
2004). PML contains three putative p53 responsive elements (REs)
in its promoter region (de Stanchina et al., 2004). p53 is able
to induce PML protein as well as PML mRNA, and to increase
the number and size of PML-NBs. PML also contributes to cel-
lular p53-dependent processes like senescence, cell-cycle arrest,
and p53-mediated apoptosis, and additionally PML arranges p53
tumor suppressor functions (de Stanchina et al., 2004). Recently,
it has been reported that PML expression is also regulated at
the translational level during oncogenic K-RAS-induced OIS in
a p53-independent manner (Scaglioni et al., 2012). The authors
show that mTOR-dependent translational control mechanisms are
important in modulating PML protein levels during oncogenic K-
RAS-induced OIS and that the PML 5′ untranslated mRNA region
plays a key role in mediating PML protein upregulation and OIS
induction (Scaglioni et al., 2012). Haupt and colleagues found that
PML interacts and co-localizes with mutant p53. PML activates
mutant p53 transcriptional activity and is important for its gain
of function in cultured human cancer cells. These findings support
the notion that as is the case for wtp53, PML is a key regulator of
mutant p53 (Haupt et al., 2009).
p73/YAP AND PML/YAP: TWO COOPERATIVE
PRO-APOPTOTIC PROTEIN COMPLEXES
p53 protein is known as the “guardian of the genome” and is the
focus of studies in understanding tumorigenesis. Another member
of the p53 family, p73, was recently discovered for its pivotal role
in DNA damage signaling. The main activities of the p53 fam-
ily occur through the transcriptional activation or repression of
target genes that encode key proteins involved in cell growth inhi-
bition, apoptosis, senescence, and differentiation (Vousden and Lu,
2002). However, the members of the family differ in their upstream
regulation by different kinases. The YAP is a critical mediator of
p73 function. It binds p73 to regulate its transcriptional activity
(Strano et al., 2001) and subsequent cell death induction (Basu
et al., 2003). This binding is negatively regulated by Akt-mediated
YAP phosphorylation (Basu et al., 2003; Figure 2) and enhanced by
DNA damage (Strano et al., 2005). Furthermore,YAP stabilizes p73
protein in a post-translational way by competing with the ITCH
E3-ligase for binding to p73 (Levy et al., 2007) and inducing its
transcriptional activity via the p300 acteyltansferase (Strano et al.,
2005). Rossi et al. (2005) have shown that Itch, a human ubiquitin
protein ligase that belongs to the Nedd4-like E3 family containing
a WW domain, binds, and ubiquitinates p73 and determines its
rapid proteosome-dependent degradation.
The promyelocytic leukemia protein (PML) has been shown to
bind p73 in the nuclear bodies (NBs) to promote p300-mediated
acetylation of p73 and to regulate its transcriptional activity
(Bernassola et al., 2004). PML is the key component of PML-NBs
that regulate a large number of cellular processes by facilitat-
ing post-translational modification of target proteins, promoting
protein–protein contacts, or by sequestering proteins. It functions
as a tumor suppressor, required for normal, caspase-dependent
apoptosis in response to DNA damage, FAS, TNF, or interferons.
It plays a role in transcription regulation, DNA damage response,
DNA repair, and chromatin organization (Salomoni and Pandolfi,
2002; Bernardi and Pandolfi, 2007; Alsheich-Bartok et al., 2008).
Therefore, Blandino’s group described the PML tumor suppressor
protein as a mediator of the YAP-p73 complex (Strano et al., 2005).
Furthermore, they demonstrated that PML was a direct tran-
scriptional target of p73/YAP, showing that PML transcriptional
activation by p73/YAP is under the negative control of the proto-
oncogenic Akt/PKB kinase (Figure 2). Importantly, PML and YAP
physically interact through their PVPVY and WW domains. This
direct interaction provides part of the mechanism by which PML
can enhance the activity of theYAP-p73 complex (Lapi et al., 2008).
Binding assays and site-specific mutagenesis have shown that the
PY “XPPXY” motif consensus binds with relatively high affinity
to the WW domain of YAP (Chen and Sudol, 1995; Sudol et al.,
1995). The PVPVY motif of PML is not a canonical consensus
sequence for YAP WW domain binding but the VPxY peptide,
along with LPxY, SPxYs peptides were shown to be exceptions that
were able to bind to YAP WW domain (Chen and Sudol, 1995;
Chen et al., 1997). This evidence may be important in suggesting
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FIGURE 2 | Involvement ofYAP in the DNA damage response. Schematic
representation of the DNA damage response induced by Cisplatin (CDDP)
treatment. It was shown to signal c-Abl-mediatedYAP phosphorylation,
resulting inYAP nuclear localization and increased p73 binding and activation
of pro-apoptotic genes. By contrast, active Akt counters this effect by
phosphorylatingYAP and sequestering it at the cytoplasmic level.
the possibility of interactions of YAP with a plethora of proteins,
which contain non-canonical WW domain binding sequences and
participating in various cellular and metabolic pathways. Together
with the specificity of the cellular contexts in which YAP binds to
its canonical or non-canonical partners, these observations may
also explain the dual role of YAP as both an oncogene and tumor
suppressor.
It has also been demonstrated that PML contains a SUMO
binding motif that is independent of its sumoylation sites neces-
sary for PML-NBs formation (Shen et al., 2006). According to a
large number of proteins associated with the PML, NBs are sumoy-
lated, and/or contain SUMO binding motifs. This suggests the
possibility that these proteins are recruited to the PML networks
through non-covalent interactions mediated by covalently bound
SUMO and SUMO binding motifs present in PML. Furthermore,
YAP was identified as a target for PML-mediated sumoylation that
blocks YAP polyubiquitylation and its subsequent degradation.
This could also be important in mediating the recruitment of
YAP/p73 complex to the PML-NBs (Lapi et al., 2008). In fact, the
stabilized YAP in the protein complex with p73, is then recruited
to PML-NBs to achieve full transcriptional activation of p73. The
spatial and temporal kinetics of the recruitment and competition
for binding must be elucidated to have a more complete picture
of this dynamic complex. All these views contribute to the idea
that YAP/PML complex could act as a bridge at the crossroads
of many signaling pathways, where the actual biological read-out
might lay in the cellular context of binding partners, including cell-
specific transcription factors or effectors (apoptosis, DNA damage
response, senescence, cancerogenesis). In any case, it is important
to stress the importance of post-translational modifications in the
regulation of YAP activity. Phosphorylation is the most common
described modification of YAP, but as demonstrated by Lapi and
colleagues, different afferent signals may modulate the choice of
the partners during physiological cell life and the onset of cancer.
THE TRANSCRIPTIONAL AXIS YAP/PML/p73 IN DNA
DAMAGE-INDUCED APOPTOSIS
The regulation of p73 activity by YAP has mainly been investigated
in the field of DNA damage signaling. As an activating cofactor
for a pro-apoptotic transcription factor, one line of thinking has
assumed that YAP plays a tumor suppressor role in cancer and
cell culture models (Oka et al., 2008; Yuan et al., 2008). However,
YAP has also been clearly identified as an oncogene and cell size
regulator in both Drosophila m. and mammalian cells (Dong et al.,
2007b; Zhao et al., 2007; Cordenonsi et al., 2011; Halder et al.,
2012).
Lapi et al. (2008) demonstrated that active Akt counters
cisplatin-induced increases in PML transcription via the YAP-
p73 complex. Cisplatin (CDDP) was shown to signal c-Abl-
mediated YAP phosphorylation, resulting in YAP nuclear local-
ization and increased p73 binding and activation of pro-apoptotic
genes (Levy et al., 2008; Figure 2). Those investigating the role
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FIGURE 3 | Central role ofYAP in proliferation inhibiting pathways.
Schematic representation of the central role of YAP in inducing the
inhibition of proliferation, by integrating and mediating different upstream
stimuli. It was shown that RASSF1A disrupts the inhibitory complex
between RAF1 and MST2 and favors the physical association between
MST2 and LATS1 concomitantly; therefore, leading toYAP1
phosphorylation and nuclear re-localization where it binds to p73 and
potentiates its apoptotic activity. Oncogenic transformation as well as
DNA damage (achieved by CDDP treatment) leads toYAP accumulation
and to its functional activation.
of YAP phosphorylation events downstream of cisplatin have
so far focused on its subcellular localization for its effect on
p73 binding, but perhaps different phosphorylations can affect
YAP stability (Levy et al., 2007). However, the molecular mecha-
nism was not described. The upregulation of YAP protein, upon
CDDP treatment, is not due to transcriptional regulation, but is
a post-translational event that correlates with an increase in YAP
sumoylation mediated by PML, since it is completely abrogated in
PML/MEFs. Elevation of YAP levels in response to DNA damage
demonstrates another level of regulation of this pathway, suggest-
ing that p73 activation must be tightly controlled to ensure quick
and efficient activation of p73 target genes in response to stress
conditions (Lapi et al., 2008).
The last findings demonstrate the existence of a positive regula-
tory loop between the p73/YAP protein complex and PML during
apoptosis triggered by CDDP in HCT116 cells (Lapi et al., 2008).
In fact PML,YAP, and p73 can be recruited on Bax and p53AIP1
apoptotic gene promoters, which contain p73 binding sites within
their promoter regions, in response to CDDP and PML binds
to its own promoter and first intron where YAP and p73 were
also recruited, and promotes its own transcriptional activation
(Figure 3).
It has been previously demonstrated that YAP requires PML
and NBs localization to coactivate p73 (Strano et al., 2005). We
describe that p73 and YAP are required not only for the transcrip-
tional activation of PML during the apoptotic response but also
for the subsequent accumulation of PML protein and formation
of NBs. As a result, PML can contribute to the p73-dependent
apoptotic response by promoting both p300-mediated acetylation
of p73 (Bernassola et al., 2004) and stabilizing YAP by inhibiting
its ubiquitin-mediated degradation.
Whether YAP-p73 regulation of PML gene transcription or
PML regulation of the YAP-p73 complex is signaled by other
stresses besides cisplatin, needs to be addressed in the future.
Based on what we have previously described, YAP is not a
bona-fide tumor suppressor, but a transcriptional co-activator
that impinges directly or indirectly on different tumor suppres-
sor pathways, here represented by p53 family, PML, and HIPPO
(Figure 3). As for transcription factors with tumor suppressor
function, YAP could also reinforce either by binding directly or
indirectly the activity of transcription factors whose gene targets
encode for oncogenic proteins. Further studies of when and how
YAP is stabilized and to which transcription factor complexes it is
recruited will help us understand the paradoxical activities of YAP
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in DNA damage and tissue growth, as well as its contradictory
roles in tumorigenesis in different tissues.
CONCLUDING REMARKS
Our work has revealed a direct crosstalk between PML and YAP,
one of the two main effectors of the Hpo tumor suppressor path-
way. This finding has several important ramifications for our
understanding of the molecular mechanism of cancer. A good
example comes from a recent study of glioblastoma multiforme
(GBM), one of the most aggressive human tumors (Okazaki et al.,
2012). The authors showed that the level of PML protein in human
glioma tissue decreased as the degree of malignancy increased. A
complete loss of PML was observed in 11.1% of GBM biopsies.
The report described solid evidence that after the treatment of
TMZ (temozolomide)-resistant glioma cells with both interferon-
β (IFN-β) and TMZ, the expression of the endogenous PML gene
and its associated protein increased. This effect was primarily
attributable to IFN-β, which activates and translocates p73/YAP
complex into the nucleus for interaction with PML to induce
glioma cell apoptosis, explaining in part the observed in vivo anti-
tumor effects. The knowledge of precise mechanisms underlying
the activation of the endogenous PML/p73/YAP axis is essential
to induce the apoptosis of specific cancer cells, in addition to the
DNA damage inflicted by the combination therapy.
We hope that the unexpected finding of “PML surfing into
the YAP-Hpo tumor suppressor pathway” will allow us to better
understand the entire Hpo signaling network, and to design sys-
tems biology approaches to fight cancers caused by the genetic
lesions that map within, and affect the network.
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